Literature DB >> 17553587

Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany.

Tom Stargardt1, Jonas Schreyögg, Reinhard Busse.   

Abstract

OBJECTIVE: To examine the price reactions of German pharmacies to changes made to OTC drug regulations in 2004. Prior to these changes, regulations guaranteed identical prices in all German pharmacies.
METHODS: Two years after market deregulation, 256 pharmacies were surveyed to determine the retail prices of five selected OTC drugs. A probit regression model was used to identify factors that increased the likelihood of price changes. In addition, 409 pharmacy consumers were interviewed to gather information on their knowledge of the regulatory changes and to better explain consumer behaviour.
RESULTS: Data was collected on a total of 1215 prices. Two years after deregulation, 23.1% of the participating pharmacies had modified the price of at least one of the five OTCs included in our study. However, in total, only 7.5% of the prices differed from their pre-deregulation level. The probit model showed that population density and the geographic concentration of pharmacies were significantly associated with price changes. Interestingly, the association with the geographic concentration of pharmacies was negative. The consumer survey revealed that 47.1% of those interviewed were aware of the deregulation.
CONCLUSIONS: Our findings indicate that, two years after deregulation, very few pharmacies had made use of individual pricing strategies; price competition between pharmacies in Germany is thus taking place only a very small scale.

Mesh:

Substances:

Year:  2007        PMID: 17553587     DOI: 10.1016/j.healthpol.2007.04.006

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  4 in total

1.  Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.

Authors:  Matthias Stoll; Christian Kollan; Frank Bergmann; Johannes Bogner; Gerd Faetkenheuer; Carlos Fritzsche; Kirsten Hoeper; Heinz-August Horst; Jan van Lunzen; Andreas Plettenberg; Stefan Reuter; Jürgen Rockstroh; Hans-Jürgen Stellbrink; Osamah Hamouda; Barbara Bartmeyer
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  Competition in the German pharmacy market: an empirical analysis.

Authors:  Jörg G Heinsohn; Steffen Flessa
Journal:  BMC Health Serv Res       Date:  2013-10-10       Impact factor: 2.655

3.  Entry and price competition in the over-the-counter drug market after deregulation: Evidence from Portugal.

Authors:  Ana Moura; Pedro Pita Barros
Journal:  Health Econ       Date:  2020-06-08       Impact factor: 3.046

4.  Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study.

Authors:  Xiaodong Guan; Haishaerjiang Wushouer; Mingchun Yang; Sheng Han; Luwen Shi; Dennis Ross-Degnan; Anita Katharina Wagner
Journal:  BMJ Open       Date:  2019-11-28       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.